Robert C Huebner

US Patent:

6379675, Apr 30, 2002

Filed:

Jan 19, 1996

Appl. No.:

08/588621

Inventors:

Robert S. Becker - Henryville PA
Robert C. Huebner - Stroudsburg PA
Maryann Gray - Bartonsville PA
Karen S. Biscardi - South Sterling PA
Lorne F. Erdile - Tassin la Demi Lune, FR
Bruno Guy - Lyons, FR

Assignee:

Connaught Laboratories, Inc. - Swiftwater PA

International Classification:

A61K 3902

US Classification:

4242341, 4241921, 4241931, 42419711, 4242371, 4242441, 530350, 435 691

Abstract:

Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

US Patent:

6451769, Sep 17, 2002

Filed:

Oct 15, 1998

Appl. No.:

09/173053

Inventors:

Robert C. Huebner - Stroudsburg PA
Jon A. Norman - San Diego CA
Xiaowu Liang - La Jolla CA
Kristin R. Carner - San Diego CA
Alan G. Barbour - Irvine CA
Catherine J. Luke - Irvine CA

Assignee:

Pasteur Merieux Serums et Vaccins - Lyons
Vical, Inc. - San Diego CA
The University of Texas System - Austin TX

International Classification:

A61K 3170

US Classification:

514 44, 435 914, 435 9141, 4353201, 435455

Abstract:

Disclosed is a vaccine against Lyme Disease or its causative agent (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.

US Patent:

6538118, Mar 25, 2003

Filed:

Apr 28, 1998

Appl. No.:

09/067453

Inventors:

Robert C. Huebner - Stroudsburg PA
Lorne F. Erdile - Stroudsburg PA
Robert S. Becker - Henryville PA
Maryann B. Gray - Bartonsville PA
Derek J. Pyle - East Stroudsburg PA

Assignee:

Connaught Laboratories, Inc. - Swiftwater PA

International Classification:

C07H 2104

US Classification:

536 231, 536 234, 536 237, 435 691, 435 697, 4351723, 4353201

Abstract:

Heterologous lipidated proteins formed recombinantly are disclosed and claimed. The expression system can be. The heterologous lipidated protein has a leader sequence which does not naturally occur with the protein portion of the lipidated protein. The lipidated protein can have the Borrelia OspA leader sequence. The protein portion can be OspC, PspA, UreA, Ure B, or a fragment thereof. Methods and compositions for forming and employing the proteins are also disclosed and claimed.

US Patent:

6984385, Jan 10, 2006

Filed:

Mar 12, 2002

Appl. No.:

10/096687

Inventors:

Robert S. Becker - Henryville PA, US
Robert C. Huebner - Stroudsburg PA, US
Maryann Gray - Bartonsville PA, US
Karen S. Biscardi - South Sterling PA, US
Lorne F. Erdile - Tassin la Demi Lune, FR
Bruno Guy - Lyons, FR

Assignee:

Connaught Laboratories, Inc. - Swiftwater PA

International Classification:

A61K 39/00

US Classification:

4241921, 4242341, 4241931, 42419711, 4242001, 4242011, 4242031, 4242371, 4242441, 530350, 435 691, 435 693, 435 697, 435 711

Abstract:

Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

US Patent:

7179596, Feb 20, 2007

Filed:

Feb 17, 2003

Appl. No.:

10/248775

Inventors:

Andrew E. Page - Kansas City MO, US
Kelly L Brown - Kansas City MO, US
David S. Alburty - Drexel MO, US
Robert C. Huebner - Liberty MO, US

Assignee:

Sceptor Industries, Inc. - Kansas City MO

International Classification:

C12Q 1/68
C12Q 1/04
C07K 4/04
C07H 21/02
C07H 21/04

US Classification:

435 6, 530350, 536 231, 435 34

Abstract:

The present invention provides a biological particle analogue, or biological analogue, that simulates a chosen biological organism or compound. The biological analogue includes a first portion that is not, in and of itself, recognized by the biological detection system, and a second portion, which provides the properties necessary for recognition by the detection system, carried by the first portion. The biological analogue is constructed in such a way as to include some important characteristics of the chosen biological organism or compound, while excluding other undesirable characteristics of the chosen biological organism or compound. The present invention is useful in testing a variety of biological detection systems.

US Patent:

7235243, Jun 26, 2007

Filed:

Jul 1, 2005

Appl. No.:

11/173364

Inventors:

Robert S. Becker - Henryville PA, US
Robert C. Huebner - Stroudsburg PA, US
Maryann Gray - Bartonsville PA, US
Karen S. Biscardi - South Sterling PA, US
Lorne F. Erdile - Tassin la Demi Lune, FR
Bruno Guy - Lyons, FR

Assignee:

Connaught Laboratories, Inc. - Swiftwater PA

International Classification:

A61K 39/00

US Classification:

4241921, 4241931, 42419711, 4242001, 4242011, 4242031, 4242341, 4242371, 4242441, 435 691, 435 693, 435 697, 435 711, 530350

Abstract:

Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

US Patent:

7635486, Dec 22, 2009

Filed:

Jan 14, 1999

Appl. No.:

09/600057

Inventors:

Edwin W. Ades - Atlanta GA, US
George M. Carlone - Stone Mountain GA, US
Barun K. De - Snellville GA, US
Jacquelyn S. Sampson - College Park GA, US
Robert C. Huebner - Stroudsburg PA, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/02
A61K 45/00
A61K 39/09

US Classification:

4242001, 424 91, 424 92, 4241841, 4241921, 4242341, 4242441, 4242781, 435243, 4352521, 4352534

Abstract:

The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of infection.

US Patent:

7960535, Jun 14, 2011

Filed:

Nov 16, 2009

Appl. No.:

12/619357

Inventors:

Edwin W. Ades - Atlanta GA, US
George M. Carlone - Stone Mountain GA, US
Barun K. De - Snellville GA, US
Jacquelyn S. Sampson - College Park GA, US
Robert C. Huebner - Stroudsburg PA, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07H 21/02
C07H 21/04
A61K 49/00

US Classification:

536 237, 536 231, 424 91, 424 92, 4241841, 4241851, 4241921, 4242001

Abstract:

The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of , which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of infection.